11 Things Primary Care Doctors Still Get Wrong About Menopause in 2025 That Are Causing Real Harm
The number of messages I get from women who were told 'you're too young' or 'let's wait and see' while they were falling apart at work, lying awake at 3am, and quietly wondering if they were losing their minds — it makes me genuinely angry. Not at doctors as people, but at a system that never prioritised updating its menopause literacy. You deserve better than that, and knowing where the gaps are is the first step to advocating for yourself.
Learn more about Rose →Treating the 2002 WHI study as the final word on HRT safety
The Women's Health Initiative trial that spooked a generation of doctors used older, synthetic progestins and oral conjugated equine estrogen in women averaging 63 years old — a population already a decade past menopause. Subsequent reanalysis and newer trials consistently show that transdermal estradiol with micronised progesterone, started within ten years of the final period, carries a substantially different risk profile. Continuing to cite the original WHI as a blanket reason to withhold HRT is not evidence-based medicine in 2025.
Ignoring the 'timing hypothesis' and delaying HRT until symptoms are severe
The timing hypothesis — supported by multiple large cohort studies and reanalysis of RCT data — indicates that hormone therapy initiated close to menopause onset carries cardiovascular and neuroprotective benefits that are largely lost when started more than ten years after the final period. Telling a 48-year-old in perimenopause to 'manage symptoms naturally first' and revisiting the conversation at 55 may actively close a protective window. Early initiation, not delayed initiation, is increasingly the evidence-supported position for healthy women with bothersome symptoms.
Missing perimenopause entirely because FSH or estrogen blood tests look 'normal'
Perimenopause is diagnosed clinically — from symptoms and menstrual pattern changes — not from a single hormone blood test. FSH and estradiol levels fluctuate wildly day to day and even hour to hour in the perimenopause transition, meaning a single 'normal' result tells a clinician almost nothing about a woman's hormonal state. A woman presenting with irregular cycles, new-onset insomnia, mood instability, and hot flushes is in perimenopause until proven otherwise, regardless of what her labs say that Tuesday morning.
Dismissing cognitive symptoms — brain fog, word loss, memory lapses — as anxiety or depression
Estrogen has well-documented roles in neurological function, including verbal memory, processing speed, and executive function, mediated through estrogen receptors distributed throughout the brain including the hippocampus and prefrontal cortex. Women in perimenopause and early menopause consistently report and demonstrate measurable cognitive changes on neuropsychological testing that are distinct from, though sometimes co-occurring with, depression. Routing every woman with cognitive complaints directly to antidepressants without considering the hormonal substrate is both clinically incomplete and deeply demoralising for patients.
Prescribing antidepressants as a first-line treatment for mood symptoms without discussing hormones
While SSRIs and SNRIs are appropriate for women with a primary depressive disorder, the perimenopausal mood instability that many women experience — characterised by sudden irritability, emotional reactivity, and low mood tightly correlated with hormonal fluctuation — has a different physiological driver than classic depression. Studies including the SWAN cohort data show that the menopausal transition itself is an independent risk period for depressive symptoms, with estrogen-based therapy showing significant mood benefits in perimenopausal but not postmenopausal women. Handing out antidepressants without a hormonal conversation is not a neutral clinical decision.
Overstating breast cancer risk from HRT while ignoring the risks of leaving symptoms untreated
The absolute increase in breast cancer risk associated with combined HRT use is frequently communicated in relative terms that distort patient perception — the commonly cited figures translate to approximately one additional case per thousand women per year of use, a risk comparable to drinking one or two glasses of wine a night or being overweight. Meanwhile, the established harms of untreated menopause — including accelerated bone loss, increased cardiovascular risk, urogenital atrophy, and sleep deprivation's downstream effects — receive far less airtime in the clinical conversation. Informed consent requires honest presentation of both sides of the ledger.
Failing to diagnose or treat genitourinary syndrome of menopause (GSM)
Genitourinary syndrome of menopause — encompassing vaginal dryness, atrophy, painful sex, recurrent UTIs, and urinary urgency — affects an estimated 50 to 60 percent of postmenopausal women, yet research consistently shows it is underdiagnosed and undertreated because neither patients nor clinicians routinely raise it. Unlike vasomotor symptoms, GSM does not improve with time and typically worsens progressively without treatment; low-dose vaginal estrogen is highly effective, carries minimal systemic absorption, and is not contraindicated for most women including many breast cancer survivors. A woman leaving a menopause consultation without a discussion of pelvic and urinary symptoms has received an incomplete assessment.
Applying a blanket HRT contraindication to all women with a history of migraine
Migraine with aura is a genuine contraindication to combined oral contraceptives due to thromboembolic risk, and that caution has been incorrectly transferred by many practitioners to HRT, which works through a fundamentally different delivery and metabolic mechanism. Transdermal estradiol does not carry the same first-pass hepatic effects and does not increase clotting factor production in the same way oral estrogen does; current guidance from the British Menopause Society and the International Headache Society supports transdermal HRT as an option for women with migraine, including migraine with aura, under appropriate specialist review. Blanket refusal based on migraine history alone is not aligned with current clinical guidance.
Underestimating the cardiovascular protective window of early HRT initiation
Observational data and reanalysis from the Nurses' Health Study and DOPS trial both support a significant reduction in cardiovascular events and cardiovascular mortality when HRT is initiated in women under 60 or within ten years of menopause onset. The older framing — that HRT is cardiovascular-neutral at best and harmful at worst — was largely an artefact of studying older, comorbid women with established atherosclerosis where estrogen may destabilise existing plaques. For healthy early postmenopausal women, current evidence tilts toward net cardiovascular benefit, a position now reflected in the 2022 NICE guideline update that explicitly references cardiovascular benefit in younger women.
Treating sleep disruption as a standalone insomnia problem rather than a hormonal symptom
The sleep architecture disruption common in perimenopause and early menopause — characterised by difficulty staying asleep, early morning waking, and fatigue despite adequate time in bed — is physiologically linked to nocturnal vasomotor events, falling progesterone (which has GABAergic, sleep-promoting properties), and HPA axis dysregulation driven by estrogen withdrawal. Prescribing Z-drugs or CBT-I without addressing the hormonal substrate can help at the margins but does not resolve the root mechanism. Women who achieve vasomotor control with HRT frequently report dramatic and rapid improvement in sleep quality, a finding reflected in multiple RCTs.
Setting arbitrary upper age limits or duration caps on HRT without individualising risk
Many women are told to stop HRT at age 60, or after five years, based on institutional habit rather than current guidance — NICE 2022 and the British Menopause Society both explicitly state that there is no arbitrary upper age limit or fixed duration after which HRT must be stopped for all women, and that the decision should be individualised based on ongoing risk-benefit assessment. For women with significant osteoporosis risk, persistent vasomotor symptoms, or quality-of-life impact from stopping, continuation well beyond 60 may be clinically appropriate. Withdrawing a treatment that is working, for a reason that isn't rooted in the individual's actual risk profile, is not evidence-based medicine.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.